4475 EXECUTIVE DRIVE, SAN DIEGO, CA
Reports First Quarter 2026 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics Issues Warrant for 17.39M Shares at $0.23
Director Departure - Allan J. Camaisa to Expire Term at 2026 Meeting
Earnings Release
Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Investor Presentation
Provides Corporate Update and Key Value Drivers for 2026
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Schedule 13G - Ownership Report
Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload